StockData
Myriad Genetics Inc logo

Myriad Genetics Inc (MYGN) stock

MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$5.54−0.03 (-0.54%)

Close on Nov 17, 2026Market cap $529.90MP/E –Yield –

Myriad Genetics Inc saw revenue fall 3.2% to $806.60M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $529.90M.

Revenue
$806.60M
-3.2% vs. a year earlier
Operating income
-$98.60M
TTM Q2 2026
EPS, diluted
-$1.19
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$529.90M
P/E ratio
–
Price to sales
0.66
Price to book
1.74
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$806.60M
Net income
-$112.60M
EPS, diluted
-$1.19
Book value per share
$3.21
Diluted shares
95M

Trading

Next earnings
Feb 22, 2027 (estimated, after the close)
Previous close
$5.57
Open
$5.54
Day's range
$5.42 – $5.71
Volume
1,119,063
Average volume (20 days)
2,090,808
Index membership
Russell 2000, Russell 3000
52-week range
$2.74 – $8.09
RSI (14 days)
52.0
Volatility (1 year)
84.2%
Relative volume
0.49×

Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.

Market cap history

Month-end market cap since 2009, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodMYGNS&P 500DifferenceMYGN per yearS&P 500 per year
1 month+39.2%-4.0%+43.2 pts
3 months+81.6%-5.0%+86.6 pts
Year to date-9.9%+8.2%−18.2 pts
1 year-16.8%+11.2%−28.0 pts
3 years-69.0%+68.5%−137.5 pts-32.3%+19.0%
5 years-80.6%+67.3%−147.9 pts-28.0%+10.8%
10 years-67.7%+291.6%−359.4 pts-10.7%+14.6%

Fifteen years at a glance

Fiscal years 2010 to 2025 and trailing twelve months, USD

Revenue

$806.60M-3.2% YoY

Gross profit

$555.20M-5.4% YoY

Operating income

-$98.60M

Net income

-$112.60M

EPS, diluted

-$1.19

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Myriad Genetics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Myriad Genetics

In Vitro & In Vivo Diagnostic Substances

Myriad Genetics is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests to assess disease risk, guide treatment decisions, and provide prenatal insights. The business focuses on three main segments: oncology, women's health, and mental health. Key products include hereditary cancer panels such as MyRisk, companion diagnostics like BRACAnalysis CDx and MyChoice CDx, tumor profiling assays including Prolaris, prenatal screens such as Prequel and Foresight, and pharmacogenomic tests like GeneSight. Its customers include patients, healthcare providers, health systems, and biopharmaceutical partners.

Company profile, executives and history

Myriad Genetics stock: common questions

What is Myriad Genetics's stock price?

MYGN closed at $5.54 on Nov 17, 2026, down 0.54% on the day. Over the past 52 weeks it traded between $2.74 and $8.09.

What is Myriad Genetics's market cap?

Myriad Genetics was worth $529.90M at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is MYGN's P/E ratio?

Myriad Genetics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.19), so it has no meaningful P/E ratio.

How much revenue does Myriad Genetics make?

Myriad Genetics reported revenue of $806.60M for the twelve months to Jun 30, 2026, down 3.2% from a year earlier.

Does Myriad Genetics pay a dividend?

No. Myriad Genetics has not paid a cash dividend over the last twelve months.

When does Myriad Genetics report earnings next?

Myriad Genetics is expected to report Q4 FY2026 results on Feb 22, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.

How has MYGN stock performed over the past year?

Including dividends, MYGN returned -16.8% over the past year, against +11.2% for the S&P 500.

How many MYGN shares are sold short?

8M shares were sold short at the latest FINRA report, 9.50% of the float, or 2.0 days of average trading volume.

Who are Myriad Genetics's competitors?

Companies most similar to Myriad Genetics by business, industry and size include QDEL, NEOG, LNTH, TECH, OPK.

See a number that looks wrong?